Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Travera Inc

Overview

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

Study Type

OBSERVATIONAL

Conditions

Stage III Breast Cancer Stage IV Breast Cancer Stage III Lung Cancer Stage IV Lung Cancer AML Multiple Myeloma in Relapse Carcinoma Carcinoma, Pancreatic Carcinoma of Lung

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Sample collection or biopsy of tumor is clinically indicated as part of SOC * Prior to preceding onto therapy for treatment Exclusion Criteria: * Unable to obtain sufficient sample

Outcomes

Primary Outcomes

Best overall response (BOR)

The best overall response to therapy over 24 months will be captured for correlation with test outcomes.

Time frame: up to 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.